The Establishment of Bortezomib Resistant Myeloma Cell Line Km3/Btz and Explore the Resistance Mechanism

Luqun Wang,Qiong Liu,Hao Li,Li Lizhen,Xin Wang
DOI: https://doi.org/10.1182/blood.v124.21.5226.5226
IF: 20.3
2014-01-01
Blood
Abstract:Background: Multiple myeloma (MM) is an incurable B-cell malignancy resulting in significant morbidity and mortality, the incidence of second place in hematological malignancies. The proteasome inhibitor bortezomib inhibits IkappaB degradation, prevents NF-kappaB activation, and induces apoptosis in MM cells, has become first-line drug to MM. Despite its promising activity in traditional chemoresistant myeloma patients, however, some patients are resistant or become refractory to bortezomib. Chauhan D et al reported that Blockade of Hsp27 overcomes bortezomib resistance in lymphoma cells (Chauhan D et al., Cancer Re, 2003). However, bortezomib resistance mechanisms in MM remain controversial, the molecular basis of this reduced responsiveness is currently not fully understood.
What problem does this paper attempt to address?